★
Trade Filings
Managers Stocks Filings Superinvestors
Signals Institutional Buying Institutional Selling Insider Activity 13D & 13G Watch Sector Rotation
Tools Stock Screener Manager Screener Compare Managers Consensus Baskets All Research Tools Data API
Learn & AI Learn Ask the Data AI Agents
News ★ Saved
About About us Methodology Contact Disclaimer
Reader
DATA PLANS

Historical data downloads: coming with accounts.

API GATEWAY

Free read-only JSON access to the site's cached data.

Dark mode

Guided View
New to markets (prices, yields, YTD, market cap)? We explain every term as you browse, in plain English. Same data, with the help built in.

Expert View
You already know the market. Just the data: clean, fast and compact, with no extra explanations. This is the default view.

Interface language
Security record

BRVE

Charts & data for BRVE on Finviz ↗ Sponsored

name pending profile ingest

2Tracked holders
+2Δ holders
289.72KShares held
$5.86MReported value
+2New positions
−0Exits
n/a How these are computed → Explain this at the Research Desk →

All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026

Who holds it · Q3 2026
#ManagerSharesΔ sharesValueTheir weightHeld
1 Geode Capital Management ✦ (passive) 288.80K New $5.84M 0.0% New 1 SEC ↗ ×2
2 Citigroup Inc 919 New $18,564 0.0% New 1 SEC ↗

“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.

New buyers

Geode Capital Management $5.84M 0.0%
Citigroup Inc $18,564 0.0%

Exited

No tracked exits this quarter.
Frequently co-owned

What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.

Insider transactions

Open-market purchases (P)

Aug 07 AH Bio Fund IV, L.P.

10% owner · 1.10M sh @ 18.00 · $19.80M

Aug 07 ORBIMED ADVISORS LLC

Director, 10% owner · 1.67M sh @ 18.00 · $30.00M

Aug 07 ORBIMED ADVISORS LLC

Director, 10% owner · 273.33K sh @ 18.00 · $4.92M

Aug 07 Chimovits Erez

Director, 10% owner · 1.67M sh @ 18.00 · $30.00M

Aug 07 Chimovits Erez

Director, 10% owner · 273.33K sh @ 18.00 · $4.92M

Open-market sales (S)

No open-market insider sales in our coverage window.

Awards, exercises and tax withholding are never counted as buys or sales here. Methodology

Beneficial ownership
Nov 09 SC 13G: Jiangsu Hengrui Pharmaceuticals Co.…

View original SEC filing ↗

Nov 05 SC 13G: FMR LLC

View original SEC filing ↗

Sep 10 SC 13D/A: ORBIMED ADVISORS LLC

13.5% of class · View original SEC filing ↗

Aug 18 SC 13D: ORBIMED ADVISORS LLC

17.2% of class · View original SEC filing ↗

Aug 14 SC 13G: Frazier Life Sciences Public Fund, L.P.

View original SEC filing ↗

Aug 14 SC 13D: AH Bio Fund IV, L.P.

11.4% of class · View original SEC filing ↗

Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR. Reporting period: Q3 2026 · Methodology · Get this via the API